Safety and Pharmacokinetics of Islatravir in Individuals with Severe Renal Insufficiency

Autor:	Randolph P. Matthews, Youfang Cao, Munjal Patel, Vanessa L. Weissler, Arinjita Bhattacharyya, Inge De Lepeleire, Stefanie Last, Juan C. Rondon, Ryan Vargo, S. Aubrey Stoch, Marian Iwamoto
Rok vydání:	2022
Předmět:	Pharmacology Infectious Diseases Deoxyadenosines Area Under Curve Leukocytes Mononuclear Humans Reverse Transcriptase Inhibitors Pharmacology (medical) Renal Insufficiency Kidney
Zdroj:	Antimicrobial Agents and Chemotherapy. 66
ISSN:	1098-6596 0066-4804
Popis:	Islatravir (MK-8591) is a high-potency reverse transcriptase translocation inhibitor in development for the treatment of HIV-1 infection. Data from preclinical and clinical studies suggest that ~30% to 60% of islatravir is excreted renally and that islatravir is not a substrate of renal transporters. To assess the impact of renal impairment on the pharmacokinetics of islatravir, an open-label phase 1 trial was conducted with individuals with severe renal insufficiency (RI). A single dose of islatravir 60 mg was administered orally to individuals with severe RI (estimated glomerular filtration rate [eGFR]30 mL/min/1.73 m
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8b42f934d81cc80da47f9c3c91e625d https://doi.org/10.1128/aac.00931-22 Zobrazit plný text záznamu